“We will continue doing what we do best -- find new therapeutics to solve this crisis. Let’s all focus on this mission and not politics.” – Dr. Jeremy Levin, Biocentury Scientists and researchers at America’s biopharmaceutical companies are working around the clock to develop vaccines,…

By Debbie Hart, President & CEO of BIONJ As a leader within the New Jersey life sciences, ensuring that patients have affordable access to prescription medicines is a leading priority for my organization and the scientists and researchers we represent. We strongly believe that policymakers at…

The Personalized Medicine Coalition has released its annual report on precision medicine trends at the Food and Drug Administration (FDA). Their analysis covers FDA approvals in 2019, including new milestones in the continued pursuit of the precision medicine paradigm—the right drug for the patient…

As a new college graduate in the early 80’s, Shawn Tomasello knew one thing for sure. She wanted a career in an industry that would constantly change; one that would keep her on her toes; allow her to always be learning.  At a career fair during her senior year, she discovered Pfizer Laboratories…

Rick Starrs, CEO of NAVREF When it comes to clinical research trials, America leads the world in providing patients with access to the latest, state-of-the-art care. However, an under-represented population in clinical studies might surprise you: veterans. To correct this shortfall,…

By 2040, experts say the number of yearly cancer cases in Africa will double. In 2018 alone, cancer deaths in Africa (over 530,000) were 30 percent higher than deaths from malaria. Clearly, a shift in disease burdens has taken place on the continent. Biotechnology and pharmaceutical companies are…

Representing all facets of the patient stakeholder community, participants in BIO’s eighth Patient and Health Advocacy Summit (#BIOSummit19) came together to proclaim: “I am BIO.” But as Dr. Julie Gerberding, executive vice president and chief patent officer at Merck and Co., who acted as the event…

For the FDA, engagement with patients, caregivers and patient advocacy organizations is a vital part of the drug development and review process. However, how that engagement happens can determine how successful it is. This was the key question addressed by the “Practices and Principles: Navigating…

Writing for the Boston Globe, Dr. Michael Rosenblatt, chief medical officer of the venture firm Flagship Pioneering, debunks the common myth that biopharmaceutical companies are “free-riding” on government research. Policymakers in Washington have long preferred to believe that scientists and…